Dr. Song  is now the team leader of the State Key Laboratory of Oncology in South China. She has long been devoted to the research on the molecular mechanism and therapeutic targets of malignant tumors such as esophageal squamous cell carcinoma and breast cancer. She has published 133 papers in which more than 60 were published in  renowned journals such as EMBO Mol Med, J Exp Med., GUT, Nat Commun., J Clin Invest., Cell Res. with a total of 6098 citations and her H-index is 46. Her research work not only revealed the novel mechanisms of tumor development and malignant progression, but also provided significant prognostic biomarkers and therapeutic targets for the potential clinical intervention of malignancies. She has obtained 4 national invention patents  and hosted 23 national / provincial  funds, including one key project supported by the National Natural Science Foundation, one national major special project, and two "973" programs (sub-project leaders). She was selected as the Leading Talent of Guangdong Special Support Program; won the first prize of Guangdong Science and Technology Award (ranked first), the second prize of China Medical Science and Technology Award (ranked first), and the second prize of Ministry of Education Natural Science Award (ranked first), the 14th Guangdong Ding Ying Science and Technology Award.

Molecular mechanism of invasion and metastasis in malignancies; tumor microenvironment; non-coding RNAs.

2002/03 - 2004/03
Post-doctoral, Northwestern University in the USA

1999/09 - 2001/07
Ph.D., Oncology, Zhongshan Medical University, Guangzhou, China.

1994/09 - 1997/07
M.S., Oncology, Zhongshan Medical University, Guangzhou, China.

1992/09 - 1994/07
B.S., Nursing, Zhongshan Medical University, Guangzhou, China.

1. Ye L, Lin C, Wang X, Li Q, Li Y, Wang M, Zhao Z, Wu X, Shi D, Xiao Y, Ren L, Jian Y, Yang M, Ou R, Deng G, Ouyang Y, Chen X, Li J, Song L*. Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer. EMBO molecular medicine 2019; 11: e10638. （IF:10.624）

2. Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, Huang S, Chen X, Lai Y, Du H, Lin C, Peng X, Song L*. Wnt5a induces and maintains prostate cancer cells dormancy in bone. The Journal of experimental medicine 2019; 216: 428-449. （IF:10.892）

3. Liu L, Lin C, Liang W, Wu S, Liu A, Wu J, Zhang X, Ren P, Li M, Song L*. TBL1XR1 promotes lymphangiogenesis and lymphatic metastasis in esophageal squamous cell carcinoma. Gut 2015; 64: 26-36. （IF:17.94）

4. Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J, Song L*. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nature communications 2014; 5: 4620. （IF:11.878）

5. Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L*. Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. The Journal of clinical investigation 2013; 123: 2576-2589. （IF:12.282）

6. Huang, Li T, Wang L, Zhang L, Yan R, Li K, Xing S, Wu G, Hu L, Jia W, Lin SC, Dang CV, Song L*, Gao P, Zhang H. Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell research 2016; 26: 1112-1130. （IF:17.848）

7. Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, Jiang L, Wu J, Li M, Song L*, Li J*.Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Molecular cancer 2017; 16: 106. （IF:10.679）

8. Wang X, Lin C, Zhao X, Liu A, Zhu J, Li X, Song L*. Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Molecular cancer 2014; 13: 106. （IF:10.679）

9. Li , Yu CP, Zhong Y, Liu TJ, Huang QD, Zhao XH, Huang H, Tu H, Jiang S, Zhang Y, Liu JH, Song L*. Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer. Annals of oncology 2012; 23: 638-646. （IF:14.196）

10. Liu L, Chen K, Wu J, Shi L, Hu B, Cheng S, Li M, Song L*. Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas. Clinical cancer research 2013; 19: 3429-3438. （IF:8.911）

11. Song L#, Gong H, Lin C, et al. Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology 2012; 143: 995-1005 e1012. （IF:19.233）

12. Song L#, Lin C, Gong H, et al. miR-486 sustains NF-kappaB activity by disrupting multiple NF-kappaB-negative feedback loops. Cell research 2013; 23: 274-289. （IF:17.848）

13. Sun L#, Song L#, Wan Q, et al. cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell research 2015; 25: 429-444. （IF:17.848）

14. Song L#, Liu L, Wu Z, et al. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. The Journal of clinical investigation 2012; 122: 3563-3578. （IF:12.282）

15. Jiang L#, Lin C#, Song L#, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. The Journal of clinical investigation 2012; 122: 33-47. （IF:12.282）

16. Song LB#, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. The Journal of clinical investigation 2009; 119: 3626-3636. （IF:12.282）

Updated May 2020